Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.97 |
| ▸ | RAB9A | P51151 | 9/20 | 0.97 |
| ▸ | NPC1 | O15118 | 8/20 | 0.97 |
| ▸ | TP53 | P04637 | 8/20 | 0.97 |
| ▸ | MAPT | P10636 | 7/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | TSHR | P16473 | 5/20 | 0.97 |
| ▸ | PKM | P14618 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | GFER | P55789 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL8559714 | 0.95 | SMN1; SMN2 (0.87) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL5553186 | 0.86 | HDAC6 (0.76) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL3627340 | 0.86 | HDAC6 (1.00) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL13650865 | 0.86 | HDAC6 (0.76) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL13650905 | 0.84 | MAPT (0.70) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL13650862 | 0.83 | MAPT (0.67) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL8407047 | 0.82 | HDAC6 (0.74) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL12692391 | 0.82 | RAB9A (1.00) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL5550021 | 0.82 | HDAC6 (0.70) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL11358930 | 0.81 | RAB9A (0.66) | SMN1; SMN2RAB9ANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143943-B1 | USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY | UNIV ILLINOIS (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1797880-A2 | Use of P53 inhibitors for the treatment of side effects of cancer therapy | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-06-20 | — | — | EP | claimed |
| US-20050222224-A1 | p53 Inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-10-06 | — | — | US | claimed |
| US-20030176318-A1 | p53 inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-09-18 | — | — | US | claimed |
| US-20030144331-A1 | p53 inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-07-31 | — | — | US | claimed |
| US-20020019425-A1 | p53 Inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-02-14 | — | — | US | claimed |
| US-20020006941-A1 | p53 inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-01-17 | — | — | US | claimed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-20090011975-A1 | TARGETED BONE MARROW PROTECTION AGENTS | SEMAFORE PHARMACEUTICALS INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1143943-B1 | USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY | UNIV ILLINOIS (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1797880-A2 | Use of P53 inhibitors for the treatment of side effects of cancer therapy | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20020019425-A1 | p53 Inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-02-14 | — | — | US | disclosed |
| US-5919799-A | OVERCOMING RESISTANCE TO AN ANTI-NEOPLASTIC AGENT OR AN ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT COMPRISING SAID ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT | NIKKEN CHEMICALS CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0816366-A1 | IMIDAZOTHIAZOLE COMPOUNDS | Nikken Chemicals Company, Limited (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-4419289-A | YELLOW COLOR FOR POLYESTERS, POLYAMIDES, AND CELLULOSE ESTERS | EASTMAN KODAK COMPANY (US) | 1983-12-06 | — | — | US | disclosed |
| US-4396547-A | INDOLE, THIADIAZOLE AND MONOAZO DYES | EASTMAN KODAK COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4354970-A | YELLOW TEXTILE DYE | EASTMAN KODAK COMPANY (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | SMN1; SMN2 22/4885RAB9A 1131/4885NPC1 2830/4885 |
| US-20090011975-A1 | TARGETED BONE MARROW PROTECTION AGENTS | APAF1, BST2, MCL1 | SMN1; SMN2 1734/4885RAB9A 3244/4885NPC1 2543/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | SMN1; SMN2 22/4885RAB9A 1131/4885NPC1 2830/4885 |
| US-20020006941-A1 | p53 inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | SMN1; SMN2 3213/4885RAB9A 3270/4885NPC1 2878/4885 |
| US-20050222224-A1 | p53 Inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | SMN1; SMN2 3213/4885RAB9A 3270/4885NPC1 2878/4885 |
| US-20030144331-A1 | p53 inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | SMN1; SMN2 3213/4885RAB9A 3270/4885NPC1 2878/4885 |
| US-20030176318-A1 | p53 inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | SMN1; SMN2 3213/4885RAB9A 3270/4885NPC1 2878/4885 |
| US-20020019425-A1 | p53 Inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | SMN1; SMN2 3213/4885RAB9A 3270/4885NPC1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.